• MS Medications

  Ocrevus Use Rises for New RRMS Patients, Drops Among PPMS Patients

  Posted by Marta Ribeiro on February 17, 2020 at 12:01 pm

  

  Overall, first-line use of Genentech’s Ocrevus for MS patients has remained stable through 2019 compared to 2018, according to Spherix Global Insights. Read more here.

  What do you think of this information?

  Marta Ribeiro replied 5 years, 4 months ago 0 Member · 0 Replies
• 0 Replies

Log In to Reply